Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.
Clin Lung Cancer
; 19(4): 331-339, 2018 07.
Article
en En
| MEDLINE
| ID: mdl-29773328
ABSTRACT
Patients with non-small-cell lung cancer, including squamous-cell lung cancer (SqCLC), typically present at an advanced stage. The current treatment landscape, which includes chemotherapy, radiotherapy, surgery, immunotherapy, and targeted agents, is rapidly evolving, including for patients with SqCLC. Prompt molecular and immune biomarker testing can serve to guide optimal treatment choices, and immune biomarker testing is becoming more important for this patient population. In this review we provide an overview of current and emerging practices and technologies for molecular and immune biomarker testing in advanced non-small-cell lung cancer, with a focus on SqCLC.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Carcinoma de Células Escamosas
/
Biomarcadores de Tumor
/
Terapia Molecular Dirigida
/
Inmunoterapia
/
Neoplasias Pulmonares
Límite:
Humans
Idioma:
En
Año:
2018
Tipo del documento:
Article